Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Shanghai Kindly Instrument-H / Equity Capital Markets

Shanghai Kindly Medical Instrument is a leading domestic player in the cardiovascular interventional device market, particularly the Percutaneous Coronary Intervention (PCI) segment. Yesterday, the company launched its book building to raise up to USD 106 million.Despite the small deal size, what interests us is that Orbimed, a specialized healthcare investor, committed USD 30 million in the deal. In this note, we will quickly look at the company’s products and pipelines. We highlight interesting findings in its operations and financials and touched upon its valuation briefly. With an undemanding valuation and market leadership in the cardiovascular device segment with decent growth, we would participate in the deal.

Shanghai Kindly Medical Instrument is a leading domestic player in the cardiovascular interventional device market, particularly the Percutaneous Coronary Intervention (PCI) segment. Yesterday, the company launched its book building to raise up to USD 106 million.Despite the small deal size, what interests us is that Orbimed, a specialized healthcare investor, committed USD 30 million in the deal. In this note, we will quickly look at the company’s products and pipelines. We highlight interesting findings in its operations and financials and touched upon its valuation briefly. With an undemanding valuation and market leadership in the cardiovascular device segment with decent growth, we would participate in the deal.

Shanghai Kindly (康德莱医疗) IPO - Cardiovascular Device Leader Backed by Strong Cornerstone

Hong Kong

Shanghai Kindly Medical Instruments Co., Ltd. produces and sells medical instruments. The Company manufactures and sells intestinal balloon catheter, inflation device, multifunction drainage tube, Shanghai Kindly Medical Instruments markets its products primarily throughout China with limited overseas.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Shanghai Kindly Instrument-H (1501 HK)

Shanghai Kindly (康德莱医疗) IPO - Cardiovascular Device Leader Backed by Strong Cornerstone

Shanghai Kindly Medical Instrument is a leading domestic player in the cardiovascular interventional device market, particularly the Percutaneous...

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)